Intravenous IgG: Biological modulating molecules

Journal of Biological Regulators and Homeostatic Agents

Volumn 23, Issue 1, 2009, Pages 1-9

  Luzi, Giuseppe ^a   Bongiorno, F ^b   Paparo Barbaro, S ^a   Bruno, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

Fc receptor (FcR); IgG Fc fraction; Immune modulation; Intravenous immunoglobulin (IVIgG); Mathematical model; Sialylated Fc

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; SIALIC ACID; SUPERANTIGEN;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE NEUTROPENIA; B LYMPHOCYTE; BONE MARROW APLASIA; CELL DIFFERENTIATION; CHORIORETINOPATHY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CHRONIC LYMPHATIC LEUKEMIA; DERMATOMYCOSIS; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; EATON LAMBERT SYNDROME; EDITORIAL; ENCEPHALITIS; ERYTHEMA INFECTIOSUM; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION; MATHEMATICAL MODEL; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; MYELOMA; MYOSITIS; NEUTROPENIA; OFF LABEL DRUG USE; PYODERMA GANGRENOSUM; RETINOCHOROIDOPATHY OF BIRDSHOT; SCLEROMYXEDEMA; SEPSIS; STIFF MAN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TOXIC EPIDERMAL NECROLYSIS; TOXIC SHOCK SYNDROME; URTICARIA; UVEITIS; VASCULITIS;

COMMUNICABLE DISEASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MODELS, BIOLOGICAL;

EID: 64249135837     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (39)

1. De Martino M, Rossi ME, Vierucci A. Gli anticorpi. Biologia e uso clinico. Annali Sclavo 1, Ed. Sclavo SpA, Siena, 1984, p 1.
2. Corbellini G. L'immunologia e la sua storia. In: G Corbellini, L'evoluzione del pensiero immunologico, Ed Bollati Boringhieri, Torino, 1990, pp. 9-57.
3. Cohn EJ, Oncley JL, Strong LE, Hughes WL, Armstrong SH. Chemical, clinical and immunological studies on the products of human plasma fractionation. I The characterization of the protein fractions of human plasma. J Clin Invest 1944; 23:417-32.
4. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the 21st century. Nat Rev Drug Discovery 2003; 2:52-62.
5. Eibl MM, Wedgwood RJ. Intravenous immunoglobulin: a review. In: FS Rosen, M Seligmann, Eds, Immunodeficiencies, 1993, pp 659-698.
6. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 42:1-11.
7. Imbach P, Barandun S, d'Apuzzo V. Intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-32.
8. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17:241-51.
9. Kazatchkine MD, Kaveri VS. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-55.
10. Simon HU, Spath PJ. IVIG - Mechanisms of action. Allergy 2003; 58:543-52.
11. Clynes R. Protective mechanisms of IVIG. Current opinion in immunology 2007; 19:646-51.
12. Mouthon L, Lortholary O. Intravenous immunoglobulins in infectious diseases; where do we stand? Clin Microbiol Infect 2003; 9:333-8.
13. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227-32.
14. Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagnostic Lab Immunology 2001; 8:859-65.
15. Bayary J, Dasgupata S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Intern Immunopharmacology 2006; 6:528-34.
16. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Imm 1997; 100:151-7.
17. Prasad NK, Papoff G, Zenner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri S. Therapeutic preparations of normal polyspecific IgG (lVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161:3781-90.
18. Anderson V, Bjork L, Skansen SU. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21-32.
19. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Ann Rev Immunol 2008; 26:513-33.
20. Neri R, lacopetti V, Bombardieri S. Farmaci "off label" in Reumatologia. Reumatismo 2007; 59:1-3.
21. Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005; 42:839-48.
22. Nimmerjahn F, Ravetch JV. The anti-inflammatory activity of IgG: the intravenous IgG paradox. JEM 2007; 204:11-15.
23. Seite SF, Shoenfeld Y, Youinou P, Hillion S. What is the content of the magic draft IVIg? Autoimmunity Rev 2008; 7:435-9.
24. Koneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulinG resulting from Fe sialylation. Science 2006; 313:670-71.
25. Guglielmetti M, Bellis M, Spycher MO, Miescher S, Vergeres G. Gene expression profiling of the effects of intravenous immunoglobulin in human whole blood. Mol Immunol 2006; 43:949-59.
26. Sapan CV, Reisner HM, Lundbland RL. Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics. Vox Sanguinis 2007; 92:197-205.
27. Sewell WAC, Jolles S. Immunomodulatory action of intravenous immunoglobulins. Immunology 2002; 107:387-93.
28. Kaveri SV, Lacroix-Desmazes S, Bayry J. The anti-inflammatory IgG. N Engl J Med 2008; 359:307-9.
29. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373-6.
30. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era. Trends Pharmacol Sciences 2004; 25:306-10.
31. Sawyer LA. Autoantibodies for the prevention and treatment of viral diseases. Antiviral Res 2000; 47: 57-63.
32. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A; StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333-40.
33. Douzinas EE, Pitaridis MT, Louris G, et al. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit Care Med 2000; 28:8-15.
34. Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001; 7:759.
35. Dalakas MC, Spath PJ, (Eds). Intravenous immunoglobulins in the Third Millennium, Parthenon Publishing Group, N.Y./London 2004.
36. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases JAMA 2004; 291:2367-75.
37. Dalgleish A. The relevance of non-linear mathematics (chaos theory) to the treatment of cancer: the role of the immune system and the potential for vaccines. QL Med 1999; 92:347-52.
38. Mayer H, Zaenker KS, Heiden U. A basic mathematical model of the immune response. Chaos 1995; 5:155-161.
39. Osbourn J, Jermutus L, Duncan A. Current methods for the generation of human antibodies for the treatment of autoimmune diseases. Drug Discov Today 2003; 8:845-51.